ACP-105
ACP-105 is a novel non-steroidal SARM that, in animal studies, delivered ~66 % of the anabolic effect of Testosterone with only 27 % of its androgenic activity. Human anecdotal reports describe a clean, energized feeling with steady recomp results.
ACP-105 is usually chosen by users looking for a supposedly lighter SARM or a lower-drama entry point. That can make it useful as a reality check on whether the user is chasing compounds for identity rather than for clear utility.
Administration: Oral compound. Most users take it with a fixed daily schedule rather than chasing short-term effect swings.
Cycle context: Treat this like a suppressive research drug, not a harmless shortcut. Labs before and after matter even when the compound is marketed as mild.
Stop or reduce if: blood pressure climbs, sleep degrades, libido crashes, or labs move sharply in the wrong direction.
Why It Stands Out
- CNS Stimulation: Users cite mild nootropic effect and elevated mood, making dieting phases easier.
- Joint Friendly: Lacks drying effect of DHT derivatives; comfortable for high-volume training.
- Minimal Bloat: Non-aromatizing and does not significantly alter mineral balance.
Practical Use
| Goal | Dose | Length | Notes |
|---|---|---|---|
| Recomp | 10 mg ED | 8 wk | Good first SARM cycle. |
| Bridge | 5 mg ED | 8-12 wk | Maintains muscle between steroid blasts. |
Safety & Side-Effects
- Suppression: Mild–moderate; mini-PCT often sufficient.
- Liver: No significant hepatotoxic signal; monitor ALT/AST as precaution.
- Lipids: Slight HDL reduction; fish oil recommended.
Bottom Line: ACP-105 offers a gentle introduction to SARMs with a favourable safety-to-reward ratio, ideal for athletes prioritizing recovery, mood and gradual body composition improvements.
The common mistake is assuming a lighter profile means no meaningful endocrine cost. Another is expecting it to matter much if the rest of the training and diet plan is still underpowered.
Compared with Ostarine, ACP-105 lives in a similar conversation about mildness, but the same rule still applies: mild does not mean irrelevant or free.
Natural suppression with reduced fertility and testicular output
Suppression, worsened lipids, and an evidence base that is much thinner than users assume
CBC / hematocrit
blood pressure
lipid panel
Uncontrolled hypertension or untreated cardiovascular disease
Pre-existing severe infertility concerns unless that risk is accepted and managed